Ascentage Pharma Group International (06855.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.6x

Market Cap

HKD 12.46B

MomentumView details →

1D Return

+1.74%

YTD Return

−33.01%

RSI (14)

51.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.6x

Market Cap

HKD 12.46B

RSI (14)

51.8

MomentumView details →

1D Return

+1.74%

YTD Return

−33.01%

ProfitabilityView details →

Gross Margin

85.11%

Net Margin

−254.62%

EBITDA Margin

−229.05%

ROE (TTM)

−468.42%

ROA (TTM)

−80.42%

Asset Turnover

0.28x

GrowthView details →

Revenue YoY

−11.75%

EPS YoY

−64.24%

FCF YoY

−4.06%

Revenue CAGR 3Y

+38.67%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−HKD 2.53

EPS Surprise

−483.68%

Beats (12Q)

0/12

Next Q EPS Est

HKD 0.03

Avg Surprise (4Q)

−483.68%

Rev Surprise

−17.43%

Capital & dividendView details →

Debt/Equity

3.76x

Current Ratio

1.22x

Quick Ratio

1.18x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.02B

Net Income (TTM)

−2.61B

Op. CF (TTM)

−1.57B

Next earningsMar 31, 2027 →

Latest newsMore news →

Ascentage Pharma appointed Dr. Faical Miyara as Chief Business Officer.16d ago

Ascentage Pharma reported interim unaudited financial results for the first half of 2026, with revenue increasing 29% year-over-year to US$44.5 million (RMB302.2 million), primarily due to increased product sales.16d ago

Similar companies

Madrigal Pharmaceuticals, Inc.MDGL Jiangsu Zenergy Battery Technologies Group Co., Ltd.03677.HK Halozyme Therapeutics, Inc.HALO Nanjing Leads Biolabs Co Ltd09887.HK Arrowhead Pharmaceuticals, Inc.ARWR Corcept Therapeutics IncorporatedCORT Find similar companies →

Latest newsMore news →

Ascentage Pharma appointed Dr. Faical Miyara as Chief Business Officer.16d ago Ascentage Pharma reported interim unaudited financial results for the first half of 2026, with revenue increasing 29% year-over-year to US$44.5 million (RMB302.2 million), primarily due to increased product sales.16d ago